Skip to content
Study details
Enrolling now

A Study of LY3867070 in Healthy Participants

Eli Lilly and Company
NCT IDNCT07021547ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

196

Study length

about 1.3 years

Ages

18–65

Locations

2 sites in CA, TX

About this study

This trial is testing a new medication called LY3867070 in healthy people. The goal is to see if the medication is safe and what side effects might occur. Blood tests will be done to understand how the body processes the medication.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take LY3867070
  • 2.Take Placebo
PhasePhase 1
Primary goalNumber of Participants with One or More Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Number of Participants with One or More Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration, Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug Administration

Secondary: PK: Maximum Concentration (Cmax) of LY3867070, Part B Pharmacodynamic (PD): Change from Baseline in Gene Expression, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3867070